GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAN-1012 SR overview
CAN-1012 is under development for the treatment of advanced metastatic solid tumors, melanoma, merkel cell carcinoma, metastatic breast cancer, metastatic renal cell carcinoma, head and neck cancer squamous cell carcinoma, sarcomas, transitional cell cancer (urothelial cell cancer), vulvar cancer, vaginal cancer, penile cancer, cervical cancer and metastatic colorectal cancer. It is administered through intratumor route as injection. The therapeutic candidate is sustained release formulation and acts by targeting TLR7.
CanWell Pharma overview
CanWell Pharma is a biopharmaceutical company engaged in developing and marketing oncology products with focus in the area of oncology. The company is headquartered in Woburn, Massachusetts, the US.
For a complete picture of CAN-1012 SR’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.